Sudeep Pharma IPO Opens: Day 1 Subscription at 33% Amidst Strong Grey Market Premium

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSatyam Jha|Published at:
Sudeep Pharma IPO Opens: Day 1 Subscription at 33% Amidst Strong Grey Market Premium
Overview

Sudeep Pharma's Initial Public Offering (IPO) opened on November 21, aiming to raise ₹895 crore. On the first day, the IPO was subscribed 33%, with Non-Institutional Investors (NII) at 52% and retail investors at 43%. The price band is ₹563-593 per share. Unlisted shares traded at a Grey Market Premium (GMP) of around 20%, indicating expectations for a strong listing.

Sudeep Pharma Limited launched its Initial Public Offering (IPO) on November 21, aiming to raise a total of ₹895 crore. The offering comprises a fresh issue of shares worth ₹95 crore and an Offer for Sale (OFS) of approximately 1.3 crore shares valued at ₹800 crore, managed by existing promoters. The IPO's price band is set between ₹563 and ₹593 per share.

On the first day of bidding, by 11 AM, the issue had garnered bids for over 32.62 lakh shares, achieving a subscription rate of 33% against an offer size of nearly 1.06 crore shares. Qualified Institutional Buyers (QIBs) had not yet submitted significant bids. Among the categories that had bid, Non-Institutional Investors (NII) subscribed 52% of their allocated portion, while retail investors subscribed 43% of their portion.

Ahead of its stock exchange listing, Sudeep Pharma's unlisted shares were trading at a Grey Market Premium (GMP) ranging from 19.89% to 20.57% over the IPO price. Data from Investorgain and IPO Watch indicates this premium, although slightly down from previous days, suggests positive market sentiment and expectations for a strong listing on November 28.

The company plans to utilize approximately ₹75.81 crore from the fresh issue proceeds for capital expenditure, specifically for procuring machinery for its production facility at Nandesari Facility 1 in Gujarat. The remaining funds will be allocated for general corporate purposes.

According to Master Capital Services, investors might consider this IPO as a potential long-term investment. They highlight the rapidly expanding Indian food and nutritional ingredients market, projected to grow from an estimated $22 billion in 2024 to $32 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 8.1%. Similarly, the Vitamins and Minerals market is expected to grow from $2.1 billion to $3.0 billion by 2029 (CAGR 8%). The domestic pharmaceutical industry itself is forecast to reach $130 billion by 2030. Sudeep Pharma, with its technology-driven manufacturing and diverse product portfolio, is seen as well-positioned to benefit from these sector growth trends.

The IPO will be open for subscription until November 25. Share allotment is anticipated by November 26, with the shares scheduled to be listed on the BSE and NSE on November 28.

Impact: This IPO offers Indian investors a new opportunity to invest in the growing specialty pharmaceutical and food ingredients sector. The subscription levels and the Grey Market Premium are key indicators of investor interest and potential listing performance, which can influence market sentiment for similar upcoming IPOs.
Rating: 8/10

Difficult Terms Explained:

  • IPO (Initial Public Offering): The first time a private company offers its shares for sale to the general public to raise capital.
  • Subscription: The process where investors express their interest in buying shares during an IPO. A subscription percentage indicates how much of the offered shares have been applied for.
  • OFS (Offer for Sale): An offer by existing shareholders of a company to sell their shares to new investors. This does not involve the company issuing new shares.
  • NII (Non-Institutional Investors): Investors who apply for shares in an IPO worth more than ₹2 lakh but are not Qualified Institutional Buyers (QIBs).
  • Retail Investors: Individual investors who apply for shares in an IPO up to a maximum of ₹2 lakh.
  • QIB (Qualified Institutional Buyers): Large institutional investors such as mutual funds, pension funds, insurance companies, and foreign institutional investors.
  • Grey Market Premium (GMP): The unofficial price at which IPO shares trade in the 'grey market' before their official listing. A positive GMP indicates strong demand and expectation of listing gains.
  • CAGR (Compound Annual Growth Rate): The mean annual growth rate of an investment over a specified period longer than one year, assuming that profits are reinvested at the end of each year.
  • Capital Expenditure: Funds used by a company to acquire, upgrade, and maintain physical assets like property, buildings, technology, or equipment.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.